Published in
Wiley, Clinical Pharmacology & Therapeutics, 5(89), p. 662-673, 2011
DOI: 10.1038/clpt.2011.34
Links
Tools
Pharmacogenetics: from bench to byte--an update of guidelines
,
M. Nijenhuis,
A. de Boer,
L. Grandia,
A. de Boer,
A. H. Maitland-Van der Zee,
H. Mulder,
G. A. P. J. M. Rongen,
R. H. N. van Schaik,
R. H. van Schaik,
T. Schalekamp,
D. J. Touw,
J. van der Weide,
J. van der Weide,
B. Wilffert
and other authors.
Full text: Download
Abstract
Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).